Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Halozyme Therapeutics Inc.

www.halozyme.com

Latest From Halozyme Therapeutics Inc.

Scrip Asks...What Does 2019 Hold For Biopharma? Part 3: Pricing, Reimbursement And Market Access

How much therapies should cost and how they should be reimbursed are questions that are expected to dominate in 2019, according to industry experts and participants surveyed by Scrip on their expectations for the coming year. This is the focus for the final installment of our three-part Scrip Asks series.

Pricing Debate Pricing Strategies

Venture Funding Deals: Relay Closes Out 2018 With $400m Series C

2018 was a banner year for venture funding, and Relay's December Series C was only the third largest VC round of the year. Other year-end financings include Millendo, Erasca, Aristea and more... 

Deals Financing

Deal Watch: Amgen Outsources Celiac Drug To Provention; Lilly, NextCure Will Co-Discover IO Drugs

Through its Provention collaboration, Amgen partnered with the team that worked on AMG 714 at Celimmune, which the big biotech bought in 2017. Lilly will partner with NextCure to use the latter's FIND-IO platform for immuno-oncology drug discovery.

Deals Business Strategies

Taking Action On Diversity, BIO Challenges CEOs To Pursue Business Benefits

Scrip spoke with Halozyme CEO Helen Torley, chair of BIO's Workforce Development, Diversity and Inclusion committee, about efforts to communicate the benefits of diverse leadership to CEOs and build a database of diverse board candidates.

Human Capital Leadership
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Alias(es)
  • Hyalozyme Therapeutics Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Halozyme Therapeutics Inc.
  • Senior Management
  • Helen Torley, Pres. & CEO
    Laurie Stelzer, SVP, CFO
    Michael J LaBarre, PhD, VP, CSO
    Kenneth A Schultz, MD, VP, Innovation, Strategy & Bus. Dev.
    Benjamin Hickey, Chief Commercial Officer
  • Contact Info
  • Halozyme Therapeutics Inc.
    Phone: (858) 794-8889
    11388 Sorrento Valley Rd.
    San Diego, CA 92121
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register